Status:
COMPLETED
12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
20-75 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-trea...
Eligibility Criteria
Inclusion
- Cigarette smokers who are motivated to stop smoking and have smoked an average of at least 10 cigarettes per day
Exclusion
- Subjects who have used a nicotine replacement product within 30 days of the study screening visit or intend to use it during the study.
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00139750
Start Date
December 1 2004
End Date
February 1 2006
Last Update
June 4 2007
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Noda, Chiba, Japan
2
Pfizer Investigational Site
Fukuoka, Fukuoka, Japan
3
Pfizer Investigational Site
Sapporo, Hokkaido, Japan
4
Pfizer Investigational Site
Yokohama, Kanagawa, Japan